Table 2 Demographic, clinical, laboratory and transient elastography findings according to the presence of metabolic associated fatty liver disease
Variables | All patients (n = 168) | MAFLD (n = 65, 38.7%) | Non-MAFLD (n = 103, 61.3%) | P value |
|---|---|---|---|---|
Demographics | ||||
Mean age ± SD – years | 40.1 ± 12.6 | 46.3 ± 12.3 | 36.3 ± 11.2 | < 0.001 |
White race– n, (%) | 168 (100) | 65(100) | 103(100) | 1.0 |
Female sex – n, (%) | 90 (53.6) | 28 (43.1) | 62 (60.2) | 0.039 |
IBD-related factors | ||||
Crohn’s disease – n, (%) | 46 (70.8) | 61 (59.2) | 0.141 | |
Montreal classification – n, (%) | ||||
A1 | 8(7.5) | 2 (4.3) | 6 (9.8) | 0.462 |
A2 | 75(70.1) | 29 (63.0) | 46 (75.4) | 0.203 |
A3 | 24(22.4) | 15 (32.6) | 9 (14.8) | 0.036 |
L1 | 56 (52.3) | 26 (56.6) | 30 (49.2) | 0.558 |
L2 | 10(9.3) | 3 (6.5) | 7 (11.5) | 0.510 |
L3 | 41(38.3) | 17 (37.0) | 24 (39.3) | 0.843 |
L4 | 0 | 0 | 0 | - |
B1 | 48(44.9) | 20 (43.5) | 28 (45.9) | 0.846 |
B2 | 36(33.6) | 15 (32.6) | 21 (34.4) | 1.000 |
B3 | 23(21.5) | 11 (23.9) | 12 (19.7) | 0.640 |
Perianal disease | 33.3 (12.3) | 16 (24.6) | 16 (15.5) | 0.161 |
Disease extension – n, (%) | ||||
E1 | 17 (27.9) | 4 (21.1) | 13 (31.0) | 0.544 |
E2 | 18 (29.5) | 7 (36.8) | 11 (26.2) | 0.545 |
E3 | 26 (42.6) | 8 (42.1) | 18 (42.9) | 1.000 |
Mean Age at IBD diagnosis ± SD – years | 33.3 ± 12.3 | 38.6 ± 12.6 | 29.9 ± 10.9 | < 0.001 |
Median IBD duration (IQR) – months | 72.0 (84.0) | 84 (89) | 72.0 (96) | 0.207 |
Tobacco use – n, (%) | 56 (33.3) | 22 (33.8) | 34 (33.0) | 1.000 |
IBD-related abdominal surgery – n, (%) | 34 (20.2) | 19 (29.2) | 15 (14.6) | 0.029 |
Family history of IBD – n, (%) | 16 (9.5) | 4 (6.2) | 12 (11.7) | 0.289 |
Mesalazine – n, (%) | 74 (44.0) | 27 (41.5) | 47 (45.6) | 0.635 |
Immunomodulators – n, (%) | 82 (48.8) | 36 (55.4) | 46 (44.6) | 0.156 |
Glucocorticoids – n, (%) | 6 (3.6) | 3 (4.6) | 3 (2.9) | 0.678 |
Biologic therapy – n, (%) | 68 (40.5) | 22 (33.8) | 46 (44.7) | 0.197 |
Anthropometric data | ||||
Mean weight ± SD – kg | 69.1 ± 12.5 | 78.4 ± 10.0 | 63.3 ± 10.3 | < 0.001 |
Mean height ± SD – cm | 166.1 ± 9.2 | 165.7 ± 9.2 | 166.4 ± 9.2 | 0.621 |
Mean BMI (SD) – kg/m2 | 25.1 ± 4.0 | 28.6 ± 3.3 | 22.9 ± 2.6 | < 0.001 |
Mean waist circumference (SD) – cm | 87.5 ± 11.5 | 96.4 ± 9.7 | 81.8 ± 8.6 | < 0.001 |
Laboratorial data | ||||
Mean Hemoglobin ± SD – g/dL | 14.0 ± 1.3 | 14.1 ± 1.3 | 13.9 ± 1.3 | 0.194 |
Median Leucocyte count (IQR) – x103μL | 6.9 (2.7) | 6.6 (2.6) | 7.2 (2.7) | 0.384 |
Mean Platelet count ± SD – x103μL | 270.7 ± 80.9 | 264.0 ± 79.3 | 274.9 ± 82.1 | 0.396 |
Median FPG (IQR) – mg/dL | 89.0 (16.8) | 95.0 (18.0) | 87.0 (16.0) | < 0.001 |
Median AST (IQR) – IU/L | 18.0 (10.0) | 19.0 (9.5) | 17.0 (10.0) | 0.103 |
Median ALT (IQR) – IU/L | 26.0 (16.0) | 29.0 (16.5) | 23.0 (15.0) | 0.001 |
Median G-GT (IQR) – IU/L | 22.0 (19.0) | 28.0 (21.5) | 19.0 (18.0) | < 0.001 |
Median AP (IQR) – IU/L | 64.0 (20.8) | 64.0 (20.5) | 64.0 (22.0) | 0.713 |
Median albumin (IQR) – g/dL | 3.8 (0.5) | 3.9 (0.4) | 3.9 (0.6) | 0.499 |
Median total bilirubin (IQR) – mg/dL | 0.5 (0.3) | 0.5 (0.4) | 0.5 (0.4) | 0.717 |
Median direct bilirubin (IQR) – mg/dL | 0.1 (0.1) | 0.1 (0.1) | 0.1 (0.1) | 0.896 |
Mean total cholesterol ± SD – mg/dL | 175.5 ± 13.1 | 181.5 ± 35.0 | 171.7 ± 34.4 | 0.076 |
Mean LDL ± SD – mg/dL | 97.0 ± 28.0 | 102.0 ± 28.8 | 93.9 ± 27.3 | 0.068 |
Mean HDL ± SD – mg/dL | 54.3 ± 13.6 | 52.2 ± 12.9 | 55.5 ± 13.9 | 0.123 |
Median triglycerides (IQR) – mg/dL | 109.0 (70.8) | 120.0 (62.5) | 96.0 (66.0) | 0.006 |
Median CRP (IQR) – mg/L | 2.9 (2.0) | 2.9 (1.5) | 2.9 (2.8) | 0.760 |
Median ESR (IQR) – mm | 10.0 (12.8) | 10.0 (12.5) | 10.0 (12.0) | 0.477 |
Median Calprotectin (IQR) – μg/g | 184.0 (559.3) | 172 (444.5) | 202 (664) | 0.264 |
Steatosis scores | ||||
Median MAFLD-S (IQR) | -1.9 (4.1) | 0.2 (1.8) | -3.6 (3.8) | < 0.001 |
Mean FLI ± SD | 33.9 ± 26.3 | 55.3 ± 23.6 | 20.4 ± 17.5 | < 0.001 |
Median HSI (IQR) | 38.1 (8.7) | 42.4 (8.8) | 36.1 (6.44) | < 0.001 |
Mean CPN-CD ± SD | - 0.6 ± 1.8 | 0.3 ± 1.4 | -1.2 ± 1.1 | < 0.001 |
TE | ||||
Median LSM (IQR) – kPa | 4.6 (1.8) | 4.8 (2.1) | 4.5 (1.9) | 0.078 |
Mean IQR/M ± SD – % | 14.0 ± 8.8 | 14.0 ± 6.0 | 15.1 ± 6.1 | 0.247 |
Mean CAP ± SD – dB/m | 249.0 ± 55.9 | 300.6 ± 36.0 | 216.4 ± 39.2 | < 0.001 |
MAFLD criteria | ||||
CAP > 248 dB/m – n, (%) | 77 (45.8) | 65 (100) | 12 (11.7) | < 0.001 |
Overweight/Obesity – n, (%) | 76 (45.2) | 59 (90.8) | 17 (16.5) | < 0.001 |
T2DM – n, (%) | 10 (6.0) | 8 (12.3) | 2 (1.9) | 0.014 |
Impaired fasting glycemia – n, (%) | 21 (12.5) | 10 (15.4) | 11 (10.7) | 0.473 |
Abnormal waist circumference – n, (%) | 51 (30.4) | 32 (49.2) | 19 (18.4) | < 0.001 |
Dyslipidemia – n, (%) | 53 (31.5) | 30 (46.2) | 23 (22.3) | 0.002 |
Arterial Hypertension – n, (%) | 20 (11.9) | 16 (24.6) | 4 (3.9) | < 0.001 |
Plasma CRP > 2 mg/L – n, (%) | 58 (34.5) | 23 (35.4) | 35 (34.0) | 0.869 |